Your browser is no longer supported. Please, upgrade your browser.
Avalo Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.91 Insider Own0.20% Shs Outstand100.49M Perf Week8.80%
Market Cap93.04M Forward P/E- EPS next Y-0.69 Insider Trans- Shs Float39.54M Perf Month-47.34%
Income-81.40M PEG- EPS next Q-0.16 Inst Own71.70% Short Float3.93% Perf Quarter-61.48%
Sales6.70M P/S13.89 EPS this Y-154.40% Inst Trans-0.70% Short Ratio2.98 Perf Half Y-66.92%
Book/sh0.40 P/B2.22 EPS next Y18.10% ROA-121.30% Target Price6.00 Perf Year-71.84%
Cash/sh- P/C- EPS next 5Y- ROE-270.30% 52W Range0.78 - 4.50 Perf YTD-47.65%
Dividend- P/FCF- EPS past 5Y4.50% ROI-284.80% 52W High-80.89% Beta1.88
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin82.80% 52W Low10.09% ATR0.12
Employees32 Current Ratio4.00 Sales Q/Q27.30% Oper. Margin- RSI (14)29.50 Volatility10.94% 11.86%
OptionableYes Debt/Eq0.81 EPS Q/Q1.80% Profit Margin- Rel Volume0.36 Prev Close0.89
ShortableYes LT Debt/Eq0.81 Earnings- Payout- Avg Volume521.58K Price0.86
Recom1.60 SMA20-25.16% SMA50-46.74% SMA200-64.94% Volume51,519 Change-3.36%
Sep-24-21Initiated RBC Capital Mkts Outperform $6
Jan-10-22 07:59PM  
Jan-06-22 07:30AM  
Dec-16-21 07:30AM  
Dec-06-21 07:30AM  
Dec-05-21 06:43AM  
Nov-11-21 07:00AM  
Nov-09-21 04:01PM  
Oct-13-21 07:00AM  
Oct-06-21 04:15PM  
Sep-20-21 07:00AM  
Sep-17-21 09:11AM  
Sep-14-21 10:23PM  
Sep-06-21 06:43AM  
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. Its product pipeline includes AVTX-002, an Anti-LIGHT mAb targeting immune-inflammatory diseases, including acute respiratory distress syndrome and moderate-to-severe inflammatory bowel disease; and AVTX-007, an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases, including multiple myeloma and Still's disease. The company also engages in developing AVTX-006, a dual mTORc1/c2 inhibitor targeting lymphatic malformations; and AVTX 800 programs (AVTX-801, AVTX-802, and AVTX-803), which are therapeutic doses of monosaccharide therapies for congenital disorders of glycosylation. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMISTICE CAPITAL, LLCDirectorJan 20Buy0.8512,00010,20846,412,000Jan 20 06:14 PM
ARMISTICE CAPITAL, LLCDirectorJan 19Buy0.8893,70082,05346,400,000Jan 20 06:14 PM
ARMISTICE CAPITAL, LLCDirectorJan 18Buy0.88206,300182,22546,306,300Jan 20 06:14 PM
ARMISTICE CAPITAL, LLCDirectorJan 14Buy0.9385,00078,97446,100,000Jan 14 05:49 PM
ARMISTICE CAPITAL, LLCDirectorJan 13Buy1.00312,700314,01346,015,000Jan 14 05:49 PM
ARMISTICE CAPITAL, LLCDirectorJan 12Buy1.0457,30059,78145,702,300Jan 14 05:49 PM
ARMISTICE CAPITAL, LLCDirectorJan 11Buy0.9616,00315,34245,645,000Jan 11 06:18 PM
ARMISTICE CAPITAL, LLCDirectorJan 10Buy0.99491,097484,61545,628,997Jan 11 06:18 PM
ARMISTICE CAPITAL, LLCDirectorJan 07Buy1.04137,900142,97545,137,900Jan 11 06:18 PM
Wilkins H JeffreyChief Medical OfficerDec 10Buy1.576,37110,00233,373Dec 14 06:19 PM
Harrell James Archie JrChief Commercial OfficerDec 10Buy1.571,0931,71636,766Dec 14 05:16 PM
Sullivan Christopher RyanChief Accounting OfficerDec 10Buy1.579551,4999,004Dec 14 05:17 PM
NEIL GARRY ARTHURChief Scientific OfficerDec 10Buy1.574,2676,69985,639Dec 14 05:15 PM
Greenway Schond L.CFODec 10Buy1.572,2313,5033,883Dec 14 05:13 PM